GBGregorio Basile

Gregorio Basile

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Gregorio Basile has a total of 82 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Long-term SARS-CoV-2 Asymptomatic Carriage in an Immunocompromised Host: Clinical, Immunological, and Virological Implications

    by Michele Spinicci, Alessio Mazzoni, Marco Coppi, Alberto Antonelli, Lorenzo Salvati, Laura Maggi, Gregorio Basile, Lucia Graziani, Nicoletta Di Lauria, Vincenzo Di Pilato, et al.

    Purpose: SARS-CoV-2 infection in immunocompromised hosts is challenging, and prolonged viral shedding can be a common complication in these patients. We describe the clinical, immunological, and virological course of a patient with eosinophilic granulomatosis with polyangiitis, who developed the status of long-term asymptomatic SARS-CoV-2 carrier for more than 7 months. Methods: Over the study period, the patient underwent 20 RT-PCR tests for SARS-CoV-2 detection on nasopharyngeal swabs. In addition, viral cultures and genetic investigation of SARS-CoV-2 were performed. As for immunological assessment, serological and specific T-cell testing was provided at different time points. Results: Despite the patient showing a deep drug-induced B and T adaptive immunity impairment, he did not experience COVID-19 progression to severe complications, and the infection remained asymptomatic during the follow-up period, but he was not able to achieve viral clearance for more than 7 months. The infection was finally cleared by SARS-CoV-2-specific monoclonal antibody treatment, after that remdesivir and convalescent plasma failed in this scope. The genetic investigations evidenced that the infection was sustained by multiple viral subpopulations that had apparently evolved intra-host during the infection. Conclusion: Our case suggests that people with highly impaired B- and T-cell adaptive immunity can prevent COVID-19 progression to severe complications, but they may not be able to clear SARS-CoV-2 infection. Immunocompromised hosts with a long-term infection may play a role in the emergence of viral variants.


  • Open Access

    Use of the FebriDx point-of-care test for the exclusion of SARS-CoV-2 diagnosis in a population with acute respiratory infection during the second (COVID-19) wave in Italy

    by Filippo Lagi, Sasha Trevisan, Matteo Piccica, Lucia Graziani, Gregorio Basile, Jessica Mencarini, Beatrice Borchi, Lorenzo Menicacci, Micol Vaudo, Valentina Scotti, et al.


  • Open Access

    Prospective Study on Incidence, Risk Factors and Outcome of Recurrent Clostridioides difficile Infections

    by Guido Granata, Nicola Petrosillo, Lucia Adamoli, Michele Bartoletti, Alessandro Bartoloni, Gregorio Basile, Matteo Bassetti, Paolo Bonfanti, Raffaella Borromeo, Giancarlo Ceccarelli, et al.

    Background: Limited and wide-ranging data are available on the recurrent Clostridioides difficile infection (rCDI) incidence rate. Methods: We performed a cohort study with the aim to assess the incidence of and risk factors for rCDI. Adult patients with a first CDI, hospitalized in 15 Italian hospitals, were prospectively included and followed-up for 30 d after the end of antimicrobial treatment for their first CDI. A case–control study was performed to identify risk factors associated with 30-day onset rCDI. Results: Three hundred nine patients with a first CDI were included in the study; 32% of the CDI episodes (99/309) were severe/complicated; complete follow-up was available for 288 patients (19 died during the first CDI episode, and 2 were lost during follow-up). At the end of the study, the crude all-cause mortality rate was 10.7% (33 deaths/309 patients). Two hundred seventy-one patients completed the follow-up; rCDI occurred in 21% of patients (56/271) with an incidence rate of 72/10,000 patient-days. Logistic regression analysis identified exposure to cephalosporin as an independent risk factor associated with rCDI (RR: 1.7; 95% CI: 1.1–2.7, p = 0.03). Conclusion: Our study confirms the relevance of rCDI in terms of morbidity and mortality and provides a reliable estimation of its incidence.


  • Tolvaptan efficacy and drug-drug interactions

    by Matteo Piccica, Gregorio Basile, Filippo Bartalesi, Gabriele Parenti, Alberto Farese, Lisa Buci, Giampaolo Corti, Alessandro Bartoloni, Alessandro Peri

    Article: Tolvaptan efficacy and drug-drug interactions - Minerva Endocrinologica 2020 September;45(3):264-5 - Minerva Medica - Journals